Payment overview · 2025
General Payments
$208.35
11 reported records · 9 companies
Healthcare provider profile · identity verified
Mark Edgar Miller, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, AR · NPI 1184676041
Verified facts
What the public records show
CMS Open Payments records show Mark Edgar Miller, M.D. received $208.35 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 986 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.49 | 20.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.21 | 18.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $29.43 | 14.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.23 | 8.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.96 | 8.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.89 | 8.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.82 | 7.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.38 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.35 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.21 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
255 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
986 | 97 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1694 | 326 |
| Eliquis | Apixaban | 986 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 984 | 179 |
| Gabapentin | Gabapentin | 974 | 167 |
| Pantoprazole Sodium | Pantoprazole Sodium | 787 | 158 |
| Trazodone Hcl | Trazodone Hcl | 773 | 160 |
| Furosemide | Furosemide | 747 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 138 |
| Sertraline Hcl | Sertraline Hcl | 675 | 124 |
| Lisinopril | Lisinopril | 663 | 117 |
| Potassium Chloride | Potassium Chloride | 589 | 121 |
| Losartan Potassium | Losartan Potassium | 522 | 120 |
| Carvedilol | Carvedilol | 511 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 448 | 86 |
| Mirtazapine | Mirtazapine | 408 | 86 |
| Metformin Hcl | Metformin Hcl | 385 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 378 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 357 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 71 |
| Quetiapine Fumarate | Quetiapine Fumarate | 331 | 55 |
| Buspirone Hcl | Buspirone Hcl | 322 | 50 |
| Divalproex Sodium | Divalproex Sodium | 295 | 39 |
| Xarelto | Rivaroxaban | 295 | 34 |
| Omeprazole | Omeprazole | 294 | 86 |
| Donepezil Hcl | Donepezil Hcl | 275 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 271 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 256 | 49 |
| Jardiance | Empagliflozin | 255 | 33 |
| Levetiracetam | Levetiracetam | 252 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 216 | 44 |
| Metformin Hcl Er | Metformin Hcl | 215 | 59 |
| Allopurinol | Allopurinol | 195 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 194 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 44 |
| Montelukast Sodium | Montelukast Sodium | 191 | 42 |
| Tramadol Hcl | Tramadol Hcl | 188 | 52 |
| Spironolactone | Spironolactone | 184 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 183 | 47 |
| Memantine Hcl | Memantine Hcl | 183 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 88 |
| Ondansetron Hcl | Ondansetron Hcl | 176 | 55 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 174 | 34 |
| Atenolol | Atenolol | 172 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 33 |
| Myrbetriq | Mirabegron | 155 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 152 | 33 |
| Clonazepam | Clonazepam | 148 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 22 |
| Risperidone | Risperidone | 136 | 21 |
| Lorazepam | Lorazepam | 134 | 48 |
| Finasteride | Finasteride | 129 | 28 |
| Baclofen | Baclofen | 128 | 27 |
| Entresto | Sacubitril/Valsartan | 125 | 13 |
| Pregabalin | Pregabalin | 125 | 32 |
| Aripiprazole | Aripiprazole | 124 | 21 |
| Famotidine | Famotidine | 120 | 44 |
| Bupropion Xl | Bupropion Hcl | 117 | 30 |
| Januvia | Sitagliptin Phosphate | 116 | suppressed |
| Olanzapine | Olanzapine | 110 | 18 |
| Farxiga | Dapagliflozin Propanediol | 102 | 29 |
| Simvastatin | Simvastatin | 99 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 27 |
| Lamotrigine | Lamotrigine | 94 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 29 |
| Sucralfate | Sucralfate | 91 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 31 |
| Lactulose | Lactulose | 89 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 42 |
| Mounjaro | Tirzepatide | 86 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 18 |
| Meloxicam | Meloxicam | 83 | 26 |
| Topiramate | Topiramate | 81 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 75 | 11 |
| Glimepiride | Glimepiride | 73 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 69 | suppressed |
| Torsemide | Torsemide | 69 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 68 | 32 |
| Ezetimibe | Ezetimibe | 68 | 16 |
| Novolog | Insulin Aspart | 68 | 19 |
| Latanoprost | Latanoprost | 65 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 11 |
| Nystatin | Nystatin | 63 | 40 |
| Rexulti | Brexpiprazole | 63 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 62 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 12 |
| Clonidine Hcl | Clonidine Hcl | 59 | 18 |
| Ondansetron Odt | Ondansetron | 59 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 18 |
| Ertapenem | Ertapenem Sodium | 57 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 57 | suppressed |
| Cephalexin | Cephalexin | 56 | 44 |
| Diltiazem 24hr Er | Diltiazem Hcl | 56 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 56 | suppressed |
| Insulin Lispro | Insulin Lispro | 54 | 17 |
| Calcium Acetate | Calcium Acetate | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 16 |
| Prednisone | Prednisone | 53 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 44 |
| Celecoxib | Celecoxib | 51 | 23 |
| Diazepam | Diazepam | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 20 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 50 | suppressed |
| Digoxin | Digoxin | 49 | suppressed |
| Gemtesa | Vibegron | 49 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 28 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | 13 |
| Propranolol Hcl | Propranolol Hcl | 47 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 24 |
| Liothyronine Sodium | Liothyronine Sodium | 44 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 33 |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 22 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Estradiol | Estradiol | 38 | 18 |
| Progesterone | Progesterone, Micronized | 38 | 15 |
| Letrozole | Letrozole | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 15 |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Azithromycin | Azithromycin | 34 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Budesonide | Budesonide | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 23 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Acarbose | Acarbose | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Insulin Aspart | Insulin Aspart | 28 | 11 |
| Lithium Carbonate | Lithium Carbonate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Xifaxan | Rifaximin | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 27 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Linzess | Linaclotide | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Phenytoin | Phenytoin | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Austedo | Deutetrabenazine | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 12 |
| Acyclovir | Acyclovir | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 17 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Tradjenta | Linagliptin | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.35 · 11 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, Ohtuvayre, REXULTI, Tymlos, VOQUEZNA, VYNDAMAX, Wegovy, XYOSTED, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error